Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
July 21, 2022 07:00 ET
|
Autolus Therapeutics plc
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Participate in William Blair’s Biotech Focus Conference 2022, New York, July 12 – 13, 2022
July 06, 2022 07:00 ET
|
Autolus Therapeutics plc
LONDON, July 06, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress
June 10, 2022 03:01 ET
|
Autolus Therapeutics plc
- AUTO4 shows high level of clinical activity with a novel targeting approach for patients with T Cell Lymphoma- AUTO1/22 demonstrates encouraging and durable responses in children ineligible for...
Autolus to hold Annual General Meeting (AGM) of Shareholders on Tuesday, June 28, 2022
May 31, 2022 16:01 ET
|
Autolus Therapeutics plc
LONDON, May 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted...
Autolus Therapeutics to Participate in the Jefferies Healthcare Conference, being held in New York from June 8 – 10, 2022
May 27, 2022 07:45 ET
|
Autolus Therapeutics plc
LONDON, May 27, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...